Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP

被引:862
作者
Spearing, MK
Post, RM
Leverich, GS
Brandt, D
Nolen, W
机构
[1] NIMH, BPB, NIH, Bethesda, MD 20892 USA
[2] Stanley Fdn Bipolar Network, Bethesda, MD 20814 USA
[3] HC Rumke Grp, NL-3500 AB Utrecht, Netherlands
关键词
methodology; global ratings; mental disorder; manic-depressive illness;
D O I
10.1016/S0165-1781(97)00123-6
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The Clinical Global Impressions Scale (CGI) was modified specifically for use in assessing global illness severity and change in patients with bipolar disorder. Criticisms of the original CGI were addressed by correcting inconsistencies in scaling, identifying time frames for comparison, clarifying definitions of illness severity and change, and separating out assessment of treatment side effects from illness improvement during treatment. A Detailed User's Guide was developed to train clinicians in the use of the new CGI-Bipolar Version (CGI-BP) for rating severity of manic and depressive episodes and the degree of change from the immediately preceding phase and from the worst phase of illness. The revised scale and manual provide a focused set of instructions to facilitate the reliability of these ratings of mania, depression, and overall bipolar illness during treatment of an acute episode or in longer-term illness prophylaxis. Interrater reliability of the scale was demonstrated in preliminary analyses. Thus, the modified CGI-BP is anticipated to be more useful than the original CGI in studies of bipolar disorder. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:159 / 171
页数:13
相关论文
共 29 条
[1]   CLINICAL GLOBAL IMPRESSIONS (ECDEU) - SOME CRITICAL COMMENTS [J].
BENEKE, M ;
RASMUS, W .
PHARMACOPSYCHIATRY, 1992, 25 (04) :171-176
[2]  
CALABRESE JR, 1993, J CLIN PSYCHOPHARM, V13, P280
[3]   EXTENDED OPEN-LABEL FLUOXETINE TREATMENT OF ADOLESCENTS WITH MAJOR DEPRESSION [J].
COLLE, LM ;
BELAIR, JF ;
DIFEO, M ;
WEISS, J ;
LAROCHE, C .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 1994, 4 (04) :225-232
[4]  
DAHLKE F, 1992, PSYCHOPHARMACOL BULL, V28, P425
[5]  
DENICOFF KD, 1997, IN PRESS J CLIN PSYC
[6]  
DEWILDE J, 1993, ACTA PSYCHIAT SCAND, V87, P141
[7]  
FIEVE RR, 1986, J CLIN PSYCHIAT, V47, P560
[8]  
Guy W., 1976, Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD, U.S. Department of Health, Education, and Welfare, Public health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, DHEW Publ No ADM 76-338, pp 218-222., P218
[9]  
HONER WG, 1995, CAN J PSYCHIAT, V40, P208
[10]   EFFICACY OF XANTINOLNICOTINATE IN PATIENTS WITH DEMENTIA [J].
KANOWSKI, S ;
FISCHHOF, PK ;
GROBEEINSLER, R ;
WAGNER, G ;
LITSCHAUER, G .
PHARMACOPSYCHIATRY, 1990, 23 (03) :118-124